|
Global X Marijuana Life Sciences Index ETF (HMMJ)
|
As of August 31, 2026
|
|
(Sector Equity)
|
|
Underlying Index
|
North American Medical Marijuana Index
|
Inception Return
(4/4/2017)
|
-12.66 %
|
|
Day High/Low
|
$7.34 / $7.30
|
|
YTD Return
|
1.29 %
|
|
52Week High/Low
|
$10.50 / $6.76
|
|
|
|
|
|
NAVPS
(9/11/2026)
|
$7.29
|
|
Change
|
$-0.01 / -0.16 %
|
Open / Close
(9/11/2026)
|
$7.34
/
$7.29
|
|
|
|
Management Fee
|
0.75 %
|
|
Traded Volume
|
2,098
|
|
Assets ($mil)
|
$42.44
|
|
Rank (1Yr)
|
-
|
|
Std Dev (3Yr)
|
32.74 %
|
|
Beta (3Yr)
|
1.62
|
|
Volatility Ranking (3Yr)
|
10/10
|
|
RRSP Eligibility
|
Yes
|
|
Open to Invest
|
Open
|
|
Annual Dividend
|
$0.10
|
|
Annual Yield
|
1.39 %
|
|
|
Objective
The investment objective of the ETF is to seek to replicate, to the extent possible, the performance of the North American Marijuana Index, net of expenses. The North American Marijuana Index is designed to provide exposure to the performance of a basket of North American publicly listed companies with significant business activities in the marijuana industry.
|
Fund Manager
Global X Investments Canada Inc.
Portfolio Manager
Global X Investments Canada Inc.
Sub-Advisor
-
|
|
Asset Allocation
(As of August 31, 2026)
|
Sector Allocation
(As of August 31, 2026)
|
Geographic Allocation
(As of August 31, 2026)
|
Top 10 Holdings
| Name | Asset | Sector | Geographic | Percent |
| Cronos Group Inc | Canadian Equity | Healthcare | Canada | 11.54% |
| Jazz Pharmaceuticals PLC | International Equity | Healthcare | European Union | 10.09% |
| Canopy Growth Corp | Canadian Equity | Healthcare | Canada | 9.22% |
| Tilray Brands Inc | US Equity | Healthcare | United States | 9.05% |
| SNDL Inc | Canadian Equity | Consumer Goods | Canada | 8.90% |
| Innovative Industrial Properties Inc | US Equity | Real Estate | United States | 8.72% |
| Aurora Cannabis Inc | Canadian Equity | Healthcare | Canada | 6.88% |
| Silver Spike Investment Corp | US Equity | Consumer Goods | United States | 5.92% |
| High Tide Inc | Canadian Equity | Healthcare | Canada | 5.76% |
| Corbus Pharmaceuticals Holdings Inc | US Equity | Healthcare | United States | 4.78% |
Performance Data
(As of August 31, 2026)
|
|
Return (%)
|
Annualized Return (%)
|
|
Return
|
1
Mth
|
3
Mth
|
6
Mth
|
YTD
|
1
Yr
|
3
Yr
|
5
Yr
|
10
Yr
|
|
Fund
|
11.04
|
3.61
|
3.64
|
1.29
|
-16.17
|
-6.41
|
-24.68
|
-
|
|
Benchmark
|
3.10
|
4.88
|
6.79
|
16.00
|
29.91
|
24.76
|
15.28
|
12.81
|
|
Quartile Ranking
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
|
Calendar Return (%)
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
2016
|
|
Fund
|
-13.00
|
-0.29
|
-18.82
|
-52.54
|
-18.99
|
-1.28
|
-33.82
|
-19.82
|
-
|
-
|
|
Benchmark
|
31.68
|
21.65
|
11.75
|
-5.84
|
25.09
|
5.60
|
22.88
|
-8.89
|
9.10
|
21.08
|
|
Quartile Ranking
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|